Abstract Number: 2907 • 2013 ACR/ARHP Annual Meeting
D1398G Variant Of Hepatocyte Growth Factor Receptor – A Potential Biomarker Of Severe Interstitial Lung Disease In African American Scleroderma Patients
Background/Purpose: Interstitial lung disease (ILD) is a major complication and leading cause of mortality in scleroderma (SSc, systemic sclerosis). The morbidity and mortality rates in…Abstract Number: 2917 • 2013 ACR/ARHP Annual Meeting
Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction
Background/Purpose: Acute intestinal pseudo-obstruction is a rare gastrointestinal manifestation of SSc with little data existing as to the demographics, clinical course, outcomes and mortality of…Abstract Number: 2739 • 2013 ACR/ARHP Annual Meeting
Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis
Background/Purpose : The purpose of this study was to identify SSc risk loci shared with other autoimmune diseases on the Immunochip and to fine-map previously…Abstract Number: 2609 • 2013 ACR/ARHP Annual Meeting
Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of the patients with systemic sclerosis (SSc) and leads to a decrease in health-related quality of…Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…Abstract Number: 2576 • 2013 ACR/ARHP Annual Meeting
Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Epoprostenol has been demonstrated to improve hemodynamics, functional class, and six-minute walk distance (6MWD) in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH…Abstract Number: 2577 • 2013 ACR/ARHP Annual Meeting
Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and idiopathic PAH (IPAH) are conditions with poor survival. There is evidence to suggest that sex…Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…Abstract Number: 1811 • 2013 ACR/ARHP Annual Meeting
Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease associated with substantial morbidity. Epidemiologic studies using large administrative databases often rely on the accuracy of…Abstract Number: 1464 • 2012 ACR/ARHP Annual Meeting
Comparison of Baseline Characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) Cohort to Patients Enrolled in Clinical Trials of Diffuse Systemic Sclerosis
Background/Purpose: Randomized clinical trials (RCTs) of treatment of diffuse systemic sclerosis (dcSSc) would benefit from a composite index that predicted efficacy better than current standard…Abstract Number: 1505 • 2012 ACR/ARHP Annual Meeting
Inactivation of Tankyrases Ameliorates Canonical Wnt Signaling and Prevents Experimental Fibrosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by aberrant activation of fibroblasts with increased release of extracellular matrix components. Canonical Wnt signaling has recently emerged as…Abstract Number: 1712 • 2012 ACR/ARHP Annual Meeting
The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis
Background/Purpose: Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg on right heart catheterization (RHC), is a leading cause of…Abstract Number: 1805 • 2012 ACR/ARHP Annual Meeting
The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor
Background/Purpose: We have previously demonstrated that the nucleoside adenosine mediates collagen production and induce dermal fibrosis in in vitro and in vivo models. IL–13 expression…Abstract Number: 2295 • 2012 ACR/ARHP Annual Meeting
Caveolin-1 Deficiency Induces Spontaneous Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells in Vitro
Background/Purpose: Recent studies demonstrated that the phenotypic transition of endothelial cells (EC) into activated mesenchymal cells, a process known an endothelial-to-mesenchymal transition (EndoMT), may be…Abstract Number: 2303 • 2012 ACR/ARHP Annual Meeting
Confirmation of TNIP1 As a Susceptibility Locus for Systemic Sclerosis in a Large Multicentre Study
Background/Purpose: Systemic sclerosis or scleroderma (SSc) is a complex autoimmune disorder that affects the connective tissue causing fibrosis in the skin and different internal organs.…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- Next Page »